This is a working overview of metabolic research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-31 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
After 30 days, photosynthetic efficiency dropped by 85% in UV-exposed samples and 46% in non-UV-exposed samples. However, within 24 hours of returning to Earth-like conditions, photosynthesis began recovering, demonstrating X. parietina's ability to repair its photosynthetic system after prolonged extreme exposure. Recovery appears to be linked to antioxidant production. Under Mars-like conditions, oxidative stress increased antioxidant levels, protecting against UV and temperature fluctuations. Over 30 days, antioxidant levels declined as the lichen neutralized reactive oxygen species (ROS), indicating an adaptive response that supports survival in extreme environments. X. parietina minimizes metabolism under extreme conditions. In the Mars simulation study, photosystem II efficiency declined under UV stress but remained active. UV-shielded samples performed better, suggesting that without radiation exposure, X. parietina could survive Mars-like cold and low pressure. Raman spectroscopy revealed carotenoid and parietin degradation after prolonged UV exposure, but enough pigment remained to protect vital cells, leaving the lichen's structure intact.
The "Second Indo-Iranian style" evolved with a few intermediate stages, expressing continuous influence from India, combined with influence from the Eastern Iran sphere, at that time occupied by the Sasanian Empire and the Hephthalites, with strong Sogdian cultural elements. The Hephthalites lost political power circa 550 CE after being defeated by the Sasanids and the Western Turks, but they remained influential for a long time, having fragmented into semi-independent Principalities. Sogdia, at the center of a new Silk Road between China to the Sasanian Empire and the Byzantine Empire became extremely prosperous around that time.
Closer Roberto Osuna converted his 25th consecutive save on May 24, breaking a club record. The streak had started the previous August 18, surpassing Brad Lidge (24 consecutive from June 21–September 28, 2005). Osuna's feat remained the franchise longest until Josh Hader converted 29 consecutive from April 7 to August 29, 2024. On May 28, A. J. Hinch obtained his 500th win as manager, as the Astros toppled the Chicago Cubs, 9–6. Chicago blasted five home runs, but Houston answered with five doubles—two by Jake Marisnick (8)—and two home runs by Alex Bregman (17). Bregman collected three RBI, and Michael Brantley had two hits and two RBI as Houston scored four times in the bottom of the fourth. Josh James (2–0) picked up the victory in relief while surrendering three runs over 2+1⁄3 frames. With injuries stacking up, on May 29 shortstop Carlos Correa sustained a bruised rib during a massage session. He was forced to join fellow All-Stars Springer and Jose Altuve on the injured list (IL) and expected to miss four to six weeks.
Sources: en.wikipedia.org
== Boron-8 == Boron-8 is an isotope of boron that undergoes β+ decay to beryllium-8 with a half-life of 771.9(9) ms. It is the strongest candidate for a halo nucleus with a loosely-bound proton, in contrast to neutron halo nuclei such as lithium-11. Although boron-8 beta decay neutrinos from the Sun make up only about 80 ppm of the total solar neutrino flux, they have a higher energy centered around 10 MeV, and are an important background to dark matter direct detection experiments. They are the first component of the neutrino floor that dark matter direct detection experiments are expected to eventually encounter.
== Mechanism of action == Unlike traditional sulfonylureas, RX871024 not only closes ATP-sensitive potassium (KATP) channels—leading to membrane depolarization, opening of voltage-gated calcium channels, and increased intracellular calcium—but also directly stimulates exocytosis of insulin-containing granules, even under conditions where calcium levels are held constant. This compound inhibits several potassium channels, including KATP, KCa, and delayed rectifier potassium channels, and interacts specifically with the Kir6.2 (KCNJ11) subunit of the KATP channel, distinguishing its mode of action from sulfonylureas, which target the sulfonylurea receptor 1 (ABCC8). Additionally, RX871024 mobilizes calcium from intracellular, thapsigargin-sensitive stores via redox-dependent pathways involving cytochrome P-450. Its insulinotropic effect is further enhanced by activation of protein kinase C and increases in diacylglycerol (DAG) levels, while protein kinase A activity appears to play a permissive role. RX871024 also modulates the phosphorylation of cytosolic proteins such as nonmuscle myosin heavy chain-A, which may be involved in insulin secretion signaling. Collectively, these multifaceted actions make RX871024 a potential lead compound for the development of novel antidiabetic therapies.
Genus Aptenodytes (Great Penguins) Aptenodytes forsteri, Emperor penguin (2014) Aptenodytes patagonicus, King penguin (2019) Genus Eudyptes (Crested Penguins) Eudyptes chrysocome, Western rockhopper penguin (2019) Eudyptes chrysolophus chrysolophus, Macaroni penguin (2019) Eudyptes chrysolophus schlegeli, Royal penguin (2019) Eudyptes filholi, Eastern rockhopper penguin (2019) Eudyptes moseleyi, Northern rockhopper penguin (2019) Eudyptes pachyrhynchus, Fiordland penguin (2019) Eudyptes robustus, Snares penguin (2019) Eudyptes sclateri, Erect-crested penguin (2019) Genus Eudyptula (Little Penguins) Eudyptula minor albosignata, White-flippered penguin (2019) Eudyptula minor minor, Little blue penguin (2019) Eudyptula novaehollandiae, Fairy penguin (2019) Genus Megadyptes (Hoiho Penguins) Megadyptes antipodes antipodes, Yellow-eyed penguin (2019) Pygoscelis (Brush-tailed Penguins) Pygoscelis adeliae, Adélie penguin (2014) Pygoscelis antarctica, Chinstrap penguin (2019) Pygoscelis papua, Gentoo penguin (2019) Genus Spheniscus (Banded Penguins) Spheniscus demersus, African penguin (2019) Spheniscus humboldti, Humboldt penguin (2019) Spheniscus magellanicus, Magellanic penguin (2019) Spheniscus mendiculus, Galápagos penguin (2019)
Sources: en.wikipedia.org
ACS Applied Materials & Interfaces. 16 (12): 14633–14644. Bibcode:2024AAMI...1614633K. doi:10.1021/acsami.4c02243. PMC 10982941. PMID 38483312. Karki, Sandeep; Malhotra, Sahil; Ijaz, Muhammad; Rollet, Nicolas; O'Cearbhaill, Eoin D.; Bini, Estela; Brayden, David J. (2026). "A pullulan-based bilayer film for buccal delivery of a GLP-1 peptide analogue". Carbohydrate Polymers. 380 125064. doi:10.1016/j.carbpol.2026.125064. PMID 41831981.
== Modulation: The process == In GC × GC two columns are connected sequentially, typically the first dimension is a conventional column and the second dimension is a short fast GC type, with a modulator positioned between them. The function of the modulator can be divided into basically three processes:
=== rRNA === Ψ is found in the large and small ribosomal subunits of all domains of life and their organelles. In the ribosome, Ψ residues cluster in domains II, IV, and V, and stabilize RNA-RNA and/or RNA-protein interactions. The stability afforded by Ψ may assist rRNA folding and ribosome assembly. Ψ may also influence the stability of local structures which impact the speed and accuracy of decoding and proofreading during translation.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.